2016
Accelerating rates of cognitive decline and imaging markers associated with &bgr;-amyloid pathology
Insel P, Mattsson N, Mackin R, Schöll M, Nosheny R, Tosun D, Donohue M, Aisen P, Jagust W, Weiner M, Weiner M, Aisen P, Weiner M, Aisen P, Petersen R, Jack C, Jagust W, Trojanowki J, Toga A, Beckett L, Green R, Saykin A, Morris J, Liu E, Green R, Montine T, Petersen R, Aisen P, Gamst A, Thomas R, Donohue M, Walter S, Gessert D, Sather T, Beckett L, Harvey D, Gamst A, Donohue M, Kornak J, Jack C, Dale A, Bernstein M, Felmlee J, Fox N, Thompson P, Schuff N, Alexander G, DeCarli C, Jagust W, Bandy D, Koeppe R, Foster N, Reiman E, Chen K, Mathis C, Morris J, Cairns N, Taylor-Reinwald L, Trojanowki J, Shaw L, Lee V, Korecka M, Toga A, Crawford K, Neu S, Saykin A, Foroud T, Potkin S, Shen L, Kachaturian Z, Frank R, Snyder P, Molchan S, Kaye J, Quinn J, Lind B, Dolen S, Schneider L, Pawluczyk S, Spann B, Brewer J, Vanderswag H, Heidebrink J, Lord J, Petersen R, Johnson K, Doody R, Villanueva-Meyer J, Chowdhury M, Stern Y, Honig L, Bell K, Morris J, Ances B, Carroll M, Leon S, Mintun M, Schneider S, Marson D, Griffith R, Clark D, Grossman H, Mitsis E, Romirowsky A, deToledo-Morrell L, Shah R, Duara R, Varon D, Roberts, CNA P, Albert M, Onyike C, Kielb S, Rusinek H, de Leon M, Glodzik L, De Santi S, Doraiswamy P, Petrella J, Coleman R, Arnold S, Karlawish J, Wolk D, Smith C, Jicha G, Hardy P, Lopez O, Oakley M, Simpson D, Porsteinsson A, Goldstein B, Martin K, Makino K, Ismail M, Brand C, Mulnard R, Thai G, Mc-Adams-Ortiz C, Womack K, Mathews D, Quiceno M, Diaz-Arrastia R, King R, Weiner M, Martin-Cook K, DeVous M, Levey A, Lah J, Cellar J, Burns J, Anderson H, Swerdlow R, Apostolova L, Lu P, Bartzokis G, Silverman D, Graff-Radford, MBBCH N, Parfitt F, Johnson H, Farlow M, Hake A, Matthews B, Herring S, van Dyck C, Carson R, MacAvoy M, Chertkow H, Bergman H, Hosein C, Black S, Stefanovic B, Caldwell C, Robin Hsiung G, Feldman H, Mudge B, Assaly M, Kertesz A, Rogers J, Trost D, Bernick C, Munic D, Kerwin D, Mesulam M, Lipowski K, Wu C, Johnson N, Sadowsky C, Martinez W, Villena T, Turner R, Johnson K, Reynolds B, Sperling R, Johnson K, Marshall G, Frey M, Yesavage J, Taylor J, Lane B, Rosen A, Tinklenberg J, Sabbagh M, Belden C, Jacobson S, Kowall N, Killiany R, Budson A, Norbash A, Johnson P, Obisesan T, Wolday S, Bwayo S, Lerner A, Hudson L, Ogrocki P, Fletcher E, Carmichael O, Olichney J, DeCarli C, Kittur S, Borrie M, Lee T, Bartha R, Johnson S, Asthana S, Carlsson C, Potkin S, Preda A, Nguyen D, Tariot P, Fleisher A, Reeder S, Bates V, Capote H, Rainka M, Scharre D, Kataki M, Zimmerman E, Celmins D, Brown A, Pearlson G, Blank K, Anderson K, Saykin A, Santulli R, Schwartz E, Sink K, Williamson J, Garg P, Watkins F, Ott B, Querfurth H, Tremont G, Salloway S, Malloy P, Correia S, Rosen H, Miller B, Mintzer J, Longmire C, Spicer K, Finger E, Rachinsky I, Rogers J, Kertesz A, Drost D, Pomara N, Hernando R, Sarrael A, Schultz S, Boles Ponto L, Shim H, Elizabeth Smith K, Relkin N, Chaing G, Raudin L, Smith A, Fargher K, Ashok Raj B. Accelerating rates of cognitive decline and imaging markers associated with &bgr;-amyloid pathology. Neurology 2016, 86: 1887-1896. PMID: 27164667, PMCID: PMC4873684, DOI: 10.1212/wnl.0000000000002683.Peer-Reviewed Original ResearchMeSH KeywordsAgedAmyloid beta-PeptidesAniline CompoundsAtrophyBiomarkersBrainCognitionCognitive DysfunctionDisease ProgressionEthylene GlycolsFemaleFluorodeoxyglucose F18HumansLongitudinal StudiesMagnetic Resonance ImagingMaleMental Status ScheduleNeuropsychological TestsPeptide FragmentsPositron-Emission TomographyRadiopharmaceuticalsRegression AnalysisConceptsMild cognitive impairmentFunctional declineNeuronal injuryCSF Aβ42Florbetapir PETAmyloid positivityRate of declineCognitive declineTemporal lobe atrophy ratesΒ-amyloid pathologyEarly Alzheimer's diseaseFluorodeoxyglucose PETAmyloid pathologyFDG-PETFuture trialsAtrophy ratesInclusion criteriaMixed-effects regressionΒ-amyloidCognitive impairmentAlzheimer's diseaseFirst signPatientsInjuryConsiderable proportion
2015
Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease
Palmqvist S, Zetterberg H, Mattsson N, Johansson P, Minthon L, Blennow K, Olsson M, Hansson O, Hansson O, Minthon L, Toresson H, Nägga K, Palmqvist S, Stomrud E, Johansson P, Nilsson C, Nilsson M, Mattsson N, Lindqvist D, Vestberg S, Janelidze S, Zetterberg H, Blennow K, Andreasson U, van Westen D, Lätt J, Mannfolk P, Nilsson M, Strandberg O, Sundgren P, Ståhlberg F, Lindberg O, Westman E, Wahlund L, Wollmer P, Smith R, Olsson T, Weiner M, Aisen P, Weiner M, Aisen P, Petersen R, Jack C, Jagust W, Trojanowki J, Toga A, Beckett L, Green R, Gamst A, Saykin A, Morris J, Potter W, Green R, Montine T, Petersen R, Aisen P, Gamst A, Thomas R, Donohue M, Walter S, Jack C, Dale A, Bernstein M, Felmlee J, Fox N, Thompson P, Schuff N, Alexander G, DeCarli C, Jagust W, Bandy D, Koeppe R, Foster N, Reiman E, Chen K, Mathis C, Morris J, Cairns N, Taylor-Reinwald L, Trojanowki J, Shaw L, Lee V, Korecka M, Toga A, Crawford K, Neu S, Beckett L, Harvey D, Gamst A, Kornak J, Saykin A, Foroud T, Potkin S, Shen L, Kachaturian Z, Frank R, Snyder P, Molchan S, Kaye J, Dolen S, Quinn J, Schneider L, Pawluczyk S, Spann B, Brewer J, Vanderswag H, Heidebrink J, Lord J, Petersen R, Johnson K, Doody R, Villanueva-Meyer J, Chowdhury M, Stern Y, Honig L, Bell K, Morris J, Mintun M, Schneider S, Marson D, Griffith R, Clark D, Grossman H, Tang C, Marzloff G, deToledo-Morrell L, Shah R, Duara R, Varon D, Roberts CAN P, Albert M, Kozauer N, Zerrate M, Rusinek H, de Leon M, De Santi S, Doraiswamy P, Petrella J, Aiello M, Arnold S, Karlawish J, Wolk D, Smith C, Given C, Hardy P, Lopez O, Oakley M, Simpson D, Ismail M, Brand C, Richard J, Mulnard R, Thai G, Mc-Adams-Ortiz C, Diaz-Arrastia R, Martin-Cook K, DeVous M, Levey A, Lah J, Cellar J, Burns J, Anderson H, Laubinger M, Apostolova L, Silverman D, Lu P, Graff-Radford N, Parfitt F, Johnson H, Farlow M, Herring S, Hake A, van Dyck C, MacAvoy M, Benincasa A, Chertkow H, Bergman H, Hosein C, Black S, Stefanovic B, Caldwell C, Robin Hsiung G, Feldman H, Assaly M, Kertesz A, Rogers J, Trost D, Bernick C, Munic D, Wu C, Johnson N, Mesulam M, Sadowsky C, Martinez W, Villena T, Turner R, Johnson K, Reynolds B, Sperling R, Rentz D, Johnson K, Rosen A, Tinklenberg J, Ashford W, Sabbagh M, Connor D, Jacobson S, Killiany R, Norbash A, Nair A, Obisesan T, Jayam-Trouth A, Wang P, Lerner A, Hudson L, Ogrocki P, DeCarli C, Fletcher E, Carmichael O, Kittur S, Borrie M, Lee T, Bartha R, Johnson S, Asthana S, Carlsson C, Potkin S, Preda A, Nguyen D, Tariot P, Fleisher A, Reeder S, Bates V, Capote H, Rainka M, Hendin B, Scharre D, Kataki M, Zimmerman E, Celmins D, Brown A, Pearlson G, Blank K, Anderson K, Saykin A, Santulli R, Englert J, Williamson J, Sink K, Watkins F, Ott B, Stopa E, Tremont G, Salloway S, Malloy P, Correia S, Rosen H, Mintzer J, Longmire C, Spicer K. Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. Neurology 2015, 85: 1240-1249. PMID: 26354982, PMCID: PMC4607601, DOI: 10.1212/wnl.0000000000001991.Peer-Reviewed Original ResearchConceptsEarly Alzheimer's diseaseCSF biomarkersEarly-stage Alzheimer's diseaseAlzheimer's diseasePET measuresAmyloid PETT-tauMCI-ADPET biomarkersAβ42/P-tauDiagnostic accuracyClass III evidenceΒ-amyloid depositionMild cognitive impairmentHigh diagnostic accuracyAβ depositionP-tauTotal tauAD dementiaCSF Aβ42Patient preferencesCSF measuresEuroimmun ELISAAlzheimer's Disease Neuroimaging Initiative studyBioFINDER study